Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4+ CTL by Hegde, Nagendra R. et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
JEM © The Rockefeller University Press $8.00
Vol. 202, No. 8, October 17, 2005 1109–1119 www.jem.org/cgi/doi/10.1084/jem.20050162
 
ARTICLE
 
1109
 
Endogenous human cytomegalovirus gB 
is presented efﬁciently by MHC class II 
molecules to CD4
 
 
 
 CTL
 
Nagendra R. Hegde,
 
1
 
 Claire Dunn,
 
1
 
 David M. Lewinsohn,
 
2
 
 
 
Michael A. Jarvis,
 
3
 
 Jay A. Nelson,
 
1,3
 
 and David C. Johnson
 
1
 
1
 
Department of Molecular Microbiology and Immunology, 
 
2
 
Division of Pulmonary and Critical Care Medicine, Veterans Affairs 
Medical Center, and 
 
3
 
Vaccine and Gene Therapy Institute, Oregon Health 
 
&
 
 Science University, Portland, OR 97239
 
Human cytomegalovirus (HCMV) infects endothelial, epithelial, and glial cells in vivo. These 
cells can express MHC class II proteins, but are unlikely to play important roles in priming 
host immunity. Instead, it seems that class II presentation of endogenous HCMV antigens in 
these cells allows recognition of virus infection. We characterized class II presentation of 
HCMV glycoprotein B (gB), a membrane protein that accumulates extensively in endosomes 
during virus assembly. Human CD4
 
 
 
 T cells specific for gB were both highly abundant in 
blood and cytolytic in vivo. gB-specific CD4
 
 
 
 T cell clones recognized gB that was expressed 
in glial, endothelial, and epithelial cells, but not exogenous gB that was fed to these cells. 
Glial cells efficiently presented extremely low levels of endogenous gB—expressed by 
adenovirus vectors or after HCMV infection—and stimulated CD4
 
 
 
 T cells better than DCs 
that were incubated with exogenous gB. Presentation of endogenous gB required sorting of 
gB to endosomal compartments and processing by acidic proteases. Although presentation 
of cellular proteins that traffic into endosomes is well known, our observations demonstrate 
for the first time that a viral protein sorted to endosomes is presented exceptionally well, 
and can promote CD4
 
 
 
 T cell recognition and killing of biologically important host cells.
 
Viruses are contained frequently by cytolytic
or cytokine-mediated functions of CD8
 
 
 
 T
cells, which recognize peptides that are de-
rived from endogenous viral proteins and are
presented on MHC class I molecules. By
contrast, CD4
 
 
 
 T cells normally provide
“help” to initiate, maintain, or amplify immune
responses by surveying for presentation of
extracellular proteins by MHC class II mole-
cules. However, it also is well established that
class II proteins can present peptides that are
derived from endogenous or intracellular
proteins. In fact, most peptides that are ex-
tracted from class II molecules are derived
from endogenous membrane proteins that
traffic into exocytic and endocytic pathways
(1, 2). Peptides that are derived from nuclear
or cytosolic proteins represent a smaller frac-
tion, and have been postulated to reach class
II loading compartments after proteasome
processing—with or without the involve-
ment of transporter associated with antigen
presentation (TAP)—by autophagy
 
 
 
or by as
yet undefined mechanisms (3–8).
Most studies of class II presentation have
focused on professional APCs—DCs, mac-
rophages, or B cells that express copious
amounts of class II molecules. Endothelial,
epithelial, and glial cells also can express class II
proteins, especially after induction by IFN-
 
 
 
,
a cytokine that is elicited commonly during virus
infections. These cells act as portals of entry,
barriers to movement of viruses between tissues,
and “sentinels” that alert the immune system of
invasion. Little is known about class II antigen
presentation in these cell types and how this
functions in control of viruses. It seems un-
likely that priming immune responses is the
outcome. In contrast to professional APCs,
these nonprofessional APCs do not possess well-
adapted phagocytic or endocytic machinery, nor
do they migrate to primary or secondary lym-
phoid organs where priming primarily occurs.
Instead, it seems more likely that these cells
express class II proteins to present endogenous
viral antigens and be recognized by CD4
 
 
 
 T
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cells. This would expand the immune repertoire to recog-
nize and—if these CD4
 
 
 
 T cells were cytolytic or expressed
anti-viral cytokines—lead to control of viruses.
Several human viruses apparently are controlled by
CD4
 
 
 
 CTLs (9–15). Cytotoxic CD4
 
 
 
 effectors may be es-
pecially important with herpesviruses: HSV, varicella-zoster
virus, EBV, and HCMV (16–19). These viruses inhibit
MHC class I antigen presentation; therefore, class II presen-
tation of viral proteins to CD4
 
 
 
 T cells may be vital to ex-
pand the degree to which the immune system can recognize
virus-infected cells. In most cases, evidence for CD4
 
 
 
 CTLs
has involved T cell clones that could lyse antigen-expressing
cells; however, it is possible that cytolytic capacity was ac-
quired during in vitro culture (20, 21). In very few instances
have in vivo cytolytic capacity of CD4
 
 
 
 CTLs been demon-
strated. Direct ex vivo CD4
 
 
 
 CTLs were described for HIV,
although these studies involved the use of superantigens to
conjugate target and T cells (14). Recently, mouse CD4
 
 
 
 T
cells specific for lymphocytic choriomeningitis virus were
shown to be cytotoxic in vivo (22).
HCMV is a ubiquitous herpes virus that promotes the
expansion of enormous numbers of CD4
 
 
 
 and CD8
 
 
 
 T cells
(23), likely because of periodic reactivation from latency
over the course of a lifetime. Although CD8
 
 
 
 T cells clearly
play a central role in containing HCMV (24), accumulating
evidence (25–27) suggests that CD4
 
 
 
 T cells also can act as
effectors directly on virus-infected cells. Patients that gen-
erate higher numbers of IFN-
 
 
 
–producing anti-HCMV
CD4
 
 
 
 T cells clear the virus faster and exhibit fewer symp-
toms (28, 29); CD4
 
 
 
 T cell clones specific to several HCMV
antigens are cytolytic (30, 31). In addition, murine cytomeg-
alovirus can be controlled by CD4
 
 
 
 T cells in vivo in the
absence of CD8
 
 
 
 T cells (32).
We previously hypothesized that CD4
 
 
 
 T cells can con-
trol HCMV infections by recognizing endogenous antigens,
viral proteins that are expressed within virus-infected cells
(33). This was based on several facets of HCMV biology.
First, HCMV infects epithelial cells in the gut, endothelial
cells throughout the body, and glial cells in the brain, and
causes pathology in each of these tissues (34). Thus, these
cells, which are important for HCMV replication and spread
in vivo, can express class II proteins, but are unlikely to be
involved in priming immunity. Second, HCMV and other
herpesviruses assemble virus particles on trans-Golgi net-
work (TGN)/endosomes (35, 36). As part of this process,
and as virions bud into cytoplasmic membranes, large quan-
tities of all HCMV structural proteins are delivered into en-
dosomal compartments where they can be processed readily
for class II presentation. This is unlike other mammalian vi-
ruses (e.g., influenza virus) that bud from the plasma mem-
brane and where antigens are presented by class II pathways
involving proteasomes and TAP (7). These observations sup-
ported the notion that HCMV proteins might be particularly
prone to processing and presentation by class II proteins.
Consistent with this premise, two HCMV membrane pro-
teins, glycoprotein B (gB) and glycoprotein H (gH), that are
extensively sorted to endosomes, are major CD4
 
 
 
 T cell tar-
gets in vivo (23), and most CTL clones that recognize gB
and gH are CD4
 
 
 
 (30, 31).
We found that as many as 1% of the total CD4
 
 
 
 T cells
in human blood recognized HCMV gB. Most gB-specific
CD4
 
 
 
 T cells that are isolated from PBMCs expressed
granzyme B, which suggested cytolytic function in vivo.
Several gB-specific CD4
 
 
 
 T cell clones also were cytolytic
and recognized glial, epithelial, and endothelial cells express-
ing endogenous gB. However, these cells could not present
exogenous (extracellular) gB. Glial cells expressing extremely
small quantities of endogenous gB stimulated CD4
 
 
 
 T cell
clones. Presentation of endogenous gB required sorting to
endosomes and endosomal proteases. Although it is well es-
tablished that model cellular antigens that are delivered to
endosomes can be presented by class II
 
 
 
proteins, these obser-
vations demonstrate for the first time that an important hu-
man pathogen is recognized by a pathway in which viral
proteins are sorted specifically to endosomes and are pre-
sented efficiently by class II molecules. Moreover, the results
support the notion that CD4
 
 
 
 T cells can play an important
role in controlling HCMV through cytolytic and cytokine-
mediated mechanisms.
 
RESULTS
Characterization and cloning of HCMV gB-specific 
CD4
 
 
 
 T cells
 
Previous studies that involved T cell clones (30, 31) sug-
gested that HCMV glycoprotein gB might be a principal
CD4
 
 
 
 T cell antigen. By ELISPOT assays, we found that
1–10% of total CD4
 
 
 
 T cells from several seropositive indi-
viduals produced IFN-
 
 
 
 in response to extracts of HCMV-
infected cells (unpublished data). In several instances, 10% of
the anti-HCMV CD4
 
 
 
 T cells (
 
 
 
1% of the total CD4
 
 
 
cells) recognized a soluble form of gB presented by DCs
(unpublished data). Given that HCMV expresses 
 
 
 
250
polypeptides, gB is a dominant, naturally occurring CD4
 
 
 
T cell antigen. We tested whether CD4
 
 
 
 T cells, purified
directly from blood and without restimulation, were able to
express and secrete granzyme B in response to His16 glial
cells that expressed gB. His16 cells were derived by stable
transfection of the class II transactivator gene into
 
 
 
U373-MG
cells (37), one of only a very few cells that HCMV infects in
vitro and which have been used extensively in studies of
HCMV immunity. The frequency of granzyme B–secreting
CD4
 
 
 
 T cells was roughly equivalent to that of IFN-
 
 
 
–
secreting T cells (Fig. 1 A). Glial cells expressing a HSV gly-
coprotein, gI, did not stimulate T cells to secrete either IFN-
 
 
 
or granzyme B (Fig. 1 A). Secretion of granzyme B requires
perforin and is directly correlated with cytolytic activity of T
cells (38). Thus, our results are consistent with the notion
that anti-gB CD4
 
 
 
 T cells are cytolytic in vivo.
24 HLA-DR17–restricted gB-specific CD4
 
 
 
 
 
T cell
clones were isolated by limiting dilution using DCs that 
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were incubated with soluble gB. Three CD4
 
 
 
 T cell clones
were tested in CTL assays. His16 glial cells expressing gB af-
ter infection with a nonreplicating adenovirus (Ad) vector
(AdtetgB) (39) were lysed by the gB-specific clones, but cells
that were infected with a control Ad vector were not (Fig. 1
B). These results support the notion that a substantial frac-
tion of HCMV-specific CD4
 
 
 
 T cells can recognize gB.
Given that all three clones were cytotoxic, and that most
gB-specific CD4
 
 
 
 T cells—as judged by IFN-
 
 
 
 secretion—
expressed granzyme, it is likely that a substantial fraction of
gB-specific CD4
 
 
 
 T cells is cytotoxic.
 
Presentation of exogenous and endogenous HCMV gB to 
CD4
 
 
 
 T cells by glial, epithelial, and endothelial cells
 
His16 cells infected with AdtetgB, that expresses full-length,
membrane-anchored gB, stimulated the gB-specific clone
gB3/F11 to produce IFN-
 
 
 
 at levels similar to DCs that
present soluble gB (Fig. 2 A). His16 cells did not present sol-
uble gB, even at 10 
 
 
 
g/ml, a dose that is 100-fold greater
than that required for substantial stimulation of gB3/F11 by
DCs that are incubated with soluble gB (Fig. 2 A and not
depicted). When supernatants from AdtetgB-infected His16
cells were transferred to other His16 cells, they failed
 
 
 
to
stimulate CD4
 
 
 
 T cells (unpublished data). It was impossible
to express endogenous gB in DCs because of poor transduc-
tion of DCs with Ad vectors, as observed previously (40).
Several other clones similarly recognized gB that was ex-
pressed endogenously in His16 cells (four shown in Fig. 2
Figure 1. Anti-gB CD4  T cells are cytotoxic. (A) His16 cells were 
infected with 30 PFUs/cell of Ad viruses expressing HCMV gB (AdtetgB) 
or HSV gI (AdtetgI) for 24 h, incubated with CD4  T cells purified from 
PBMCs, and ELISPOT assays were performed for IFN-  or granzyme B 
(GrB). Error bars denote standard deviations, and data points without error 
bars represent differences that are too small. His16 cells were infected 
with 10 PFUs/cell of AdtetgB (B) or 100 PFUs/cell of AdTbH9 (C) for 24 h, 
labeled with Na2
51CrO4, and then incubated with anti-gB CD4  T cell 
clones (gB10/G3, gB10/H5, or gB100/2) or with mtb39-specific CD4  T cell 
clone, TbH9-9, at various effector/target ratios for 24 h, and the specific 
release of 51Cr was determined.
Figure 2. Presentation of endogenous and exogenous gB to CD4  
T cell clones. (A) Autologous DCs (104) were incubated with 1  g of 
soluble gB and 4   104 anti-gB CD4  T cell clone gB3/F11. His16 glial cells 
were infected with AdtetgB (200 PFUs/cell) for 24 h, then incubated with 
4   104 clone gB3/F11 or incubated with 1 or 10  g of soluble gB and 
simultaneously with 4   104 clone gB3/F11. (B) His16 cells were infected 
with AdtetgB or AdtetgI (30 PFUs/cell) for 24 h before addition of T cells, 
or incubated with 10  g/ml of soluble gB or soluble gE/gI and with gB-
specific clones gB3/F5, gB10/G3, gB10/H5, or gB100/2. (C) Class II–expressing 
gastric epithelial cells (2E12) or IFN- –stimulated endothelial cells (BB19, 
brain; DMVEC, dermal vascular; HPV-AEC, aortic) were infected with AdtetgB 
or AdtetgI for 24 h or incubated with 10  g of soluble gB or gE/gI and 
with CD4  T cell clone gB10/H5. IFN-  produced by the CD4  T cells was 
measured by ELISA after 24 h. 
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B), but most did not recognize exogenous gB or were stim-
ulated only weakly with high concentrations (50–100 
 
 
 
g/
ml) of soluble gB that was incubated for extended periods
(not depicted).
These observations were extended to epithelial and endo-
thelial cells. Class II transactivator–transfected 2E12 gastric
epithelial cells, which constitutively express class II proteins
and three different endothelial cell lines that were induced to
express class II proteins with IFN-
 
 
 
, also presented endoge-
nous gB, but not soluble gB (Fig. 2 C). Similar results were
obtained with other endothelial cells (unpublished data).
These cells are immortal lines but mimic properties of un-
transformed epithelial and endothelial cells; 2E12 cells can be
infected by EBV (41) and the endothelial lines can be in-
fected by HCMV (unpublished data). We concluded that
glial, epithelial, and endothelial cells proficiently presented
endogenous, but not exogenous, gB—by class II proteins—to
CD4
 
 
 
 T cells.
 
Glial cells can internalize soluble gB and present gB peptides 
and other exogenous antigens
 
The failure of glial, endothelial, and epithelial cells to present
exogenous gB might relate to an inability to internalize gB.
HCMV gB binds to cell surface heparan sulfate proteogly-
cans (42), which are internalized slowly (43). We used iodi-
nated gB to evaluate uptake by His16 glial cells, and found
that these cells internalized soluble 
 
125
 
I-labeled gB, albeit
slowly; 
 
 
 
40% of the bound gB was internalized after 90 min
(Fig. 3 A).
To determine whether His16 cells could present gB pep-
tides, cells were incubated with pools of 15-mers, overlap-
ping by 10 residues, encompassing residues 1–440 (gB-N) or
431–907 (gB-C). A pool of peptides, including all of
HCMV UL18, served as a negative control. Three different
clones recognized gB-C, but not gB-N or UL18 peptide
pools (Fig. 3 B; only one clone shown). The level of stimu-
lation of all three clones at 400 pg/ml of peptides was similar
to that obtained with His16 cells that were infected with 3–5
PFUs/cell of AdtetgB (unpublished data). Because our
clones recognize soluble gB (residues 25–692) and a peptide
mixture encompassing residues 431–907, one or more
epitope(s) is located within residues 431–692.
To ascertain whether His16 cells could present another
exogenous antigen, the cells were incubated with a 40-kD
soluble, 
 
Escherichia coli
 
-produced, recombinant tuberculosis
(TB) protein, mtb39—a member of a family of related TB
proteins (44). Presentation to mtb39-specific CD4
 
 
 
 T cell
clone TbH9-9 (which recognizes residues 133–147) was as-
sessed (37, 45). His16 cells that were incubated with 1 
 
 
 
g/ml
of mtb39 stimulated TbH9-9 cells well compared with cells
that expressed endogenous, Ad-delivered mtb39 (Fig. 3 C).
Note that cells were infected with relatively high doses of
AdTbH9, and in this case, mtb39 is linked to a signal se-
quence and is secreted,
 
 
 
but also likely fills the exocytic path-
way (46). Together, these results show that His16 cells are ca-
pable of internalizing and presenting another soluble protein
to CD4
 
 
 
 T cells, but do not present extracellular gB well.
 
Relative efficiency of presentation of endogenous gB
 
Nonprofessional APCs are not as capable as professional
APCs at antigen capture, processing, and presentation. Nev-
ertheless, several gB-specific CD4
 
 
 
 T cell clones were stim-
ulated to similar or higher levels by AdtetgB-infected His16
cells, compared with DCs that presented soluble gB (Fig. 2
A, and not depicted). When APCs were limiting, His16 cells
expressing gB stimulated gB100/2 T cells better than did
DCs that were incubated with exogenous gB (Fig. 4 A). Ad-
ditionally, His16 cells expressing endogenous mtb39, ex-
Figure 3. Glial cells internalize soluble gB, and present gB peptides 
and a soluble TB antigen. (A) His16 cells were incubated with 125I-gB at 
4 C, washed, warmed to 37 C, and the cell surface gB was removed with
citrate buffer before counting cell-associated (internalized) 125I. Background 
(cells not warmed to 37 C) was subtracted from each value. (B) His16 cells 
were incubated with pools of peptides (15 mers overlapping by 10 residues) 
making up the NH2-terminal (gB-N, residues 1–440) or the COOH-terminal 
(gB-C, residues 430–907) half of gB or all of UL18, for 6 h before incubation 
with gB10/G3 CD4  T cells for 24 h. (C) His16 cells were incubated with
medium alone (no Ag) or with 1  g/ml of soluble mtb39, and TbH9-9 (mtb39-
specific) T cells, or were infected with 100 PFUs/cell of AdTbH9 or AdtetgB 
for 24 h before addition of TbH9-9 T cells. IFN-  was measured in B and C.JEM VOL. 202, October 17, 2005 1113
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pressed using an Ad vector, also stimulated TbH9-9 T cells
approximately as well as syngeneic lymphoblastoid cell lines
(LCLs) that were incubated with soluble mtb39 (unpub-
lished data). As a second measure of the efficiency of presen-
tation of endogenous gB, His16 cells were infected with low
doses of AdtetgB. Significant  stimulation of two different
gB-specific clones was observed with His16 cells that were
infected using as little as 0.78–1.5 PFUs/cell of AdtetgB;
half-maximal presentation occurred at  5 PFUs/cell (Fig. 4
B). These Ad vectors do not replicate in His16 cells and at
these low virus doses, gB expression could not be detected
by radiolabeling or Western blots (unpublished data). Thus,
presentation of gB by His16 cells—as measured by stimula-
tion of T cell clones—is dependent on gB concentrations in
the APCs, and extremely low quantities of gB are sufficient
for T cell stimulation. Although the APCs and the source of
antigen were different in Fig. 4 A, when APCs were limit-
ing, T cell stimulation was reduced or extinguished. Con-
clusions about antigen presentation must be tempered by the
fact that antigen presentation was measured indirectly and by
using T cell clones that were selected for gB recognition.
However, coupled with the results in Fig. 7, our observa-
tions are consistent with the conclusion that His16 cells can
present endogenous gB very efficiently as compared with
professional APCs.
Endogenous presentation requires endosomal proteases 
and not proteasomes
Endogenous, cytoplasmic proteins can be degraded by pro-
teasomes and reach endosomes/lysosomes through TAP or
by undefined mechanisms (3, 7, 8). Processing and presenta-
tion of endogenous gB was not affected by the proteasome
inhibitors, lactacystin (Fig. 5 A) or MG132 (not depicted).
Similarly, HSV ICP47, a specific inhibitor of TAP (47), had
no effect (unpublished data). By contrast, leupeptin, which
inhibits cysteine and serine proteases, completely blocked gB
presentation (Fig. 5 A). Cathepsins contribute to progressive
fragmentation of the protein invariant chain (Ii); therefore, it
was reasonable that 50  M leupeptin inhibited processing of
Ii and reduced loading of class II complexes. However, pre-
sentation of exogenous mtb39 was unaffected at lower leu-
Figure 4. Efficiency of presentation of exogenous gB by DCs versus 
endogenous gB by glial cells. (A) Various numbers of His16 cells or 
autologous DCs were incubated with 1  g/ml of soluble gB (sol gB) at 
the time of adding T cells or were infected with 10 PFUs/cell of AdtetgB 
for 24 h before adding T cells. 4   104 gB100/2 anti-gB CD4  T cells were 
used in all cases. (B) His16 cells were infected with various doses of AdtetgB 
for 24 h before incubation with gB10/G3 or gB10/H5 T cell clones for 24 h. 
In both cases, IFN-  was measured.
Figure 5. Presentation of endogenous gB occurs in endosomes. 
(A) His16 cells were treated with 50  M leupeptin or pepstatin, or 10  M 
brefeldin A, bafilomycin, or lactacystin for 30 min, infected with AdtetgB 
(3 PFUs/cell) for 24 h in the presence of the inhibitors, washed, fixed with 
0.1% p-formaldehyde, and then incubated for 24 h with gB100/2 T cells. 
(B) His16 cells were treated with the indicated concentrations of leupeptin, 
infected with AdtetgB, and used in T cell assays similar to those in (A), 
using gB10/H5 and gB100/2 T cell clones. Other His16 cells were incubated 
with 2  g/ml soluble mtb39 (sol mtb39) and TbH9-9 (mtb39-specific) 
T cells. IFN-  was measured in both cases.ENDOGENOUS ANTIGEN PRESENTATION TO CD4  CTL | Hegde et al. 1114
peptin concentrations (2.5–5  M), yet presentation of en-
dogenous gB was reduced substantially (Fig. 5 B). A second
inhibitor, pepstatin, which blocks aspartyl proteases, did not
inhibit gB presentation (Fig. 5 A). Brefeldin A, an inhibitor
of ER to Golgi transport, and bafilomycin A, an inhibitor of
vacuolar acidification, also blocked presentation of gB but
both potentially can inhibit transport or maturation of class
II proteins. We concluded that endogenous gB is processed
by endosomal proteases and not by proteasomes.
Presentation of gB requires cytoplasmic sorting sequences
The cytoplasmic tail (CT) domain of HCMV gB contains
several sorting sequences that are responsible for extensive
accumulation of gB in the TGN/endosomes (48), a prelude
to virion assembly (35, 36). We reasoned that the targeting
of gB to TGN/endosomes would result in efficient class II–
mediated presentation of gB. To examine this, Ad vectors
expressing mutant forms of gB were constructed: (a) gB CT
lacks all of the CT domain, except for three juxtamembrane
residues; (b) gB-KKSL contains four additional residues at
the extreme COOH terminus that recycle the protein back
to the ER (49); and (c) gB-KKSLAL is a control protein that
contains two additional residues that revert the KKSL phe-
notype to WT (Fig. 6 A). FACS analyses indicated extensive
accumulation of gB CT on the cell surface, but WT gB,
gBKKSL, and gBKKSLAL were internal (Fig. 6 B). Confo-
cal analyses indicated that WT gB was in perinuclear vesi-
cles, some of which stained with anti–HLA-DM antibodies
(Fig. 6 C), as well as with several TGN and endosome mark-
ers (not depicted). gB-KKSL colocalized with the ER
marker protein disulfide isomerase (Fig. 6 C), and unlike
WT gB and gB-KKSLAL, gB-KKSL was not proteolytically
cleaved by furin, a TGN-localized protease (not depicted).
Three CD4  T cell clones recognized WT gB and gB-
KKSLAL, but not gB-KKSL or gB CT (Fig. 6 D). We con-
cluded that gB must be sorted to the TGN/endosomes in
order to be presented, and gB that was transported to the cell
surface or retained in the ER was not presented.
Class II presentation of gB in HCMV-infected cells 
and effects of US2 and US3
Laboratory strains of HCMV replicate efficiently only in cul-
tured human fibroblasts (34). Recently, HCMV clinical iso-
lates that infect other cell types were described (50). The
clinical strain, HCMV TR efficiently infected His16 cells
(not depicted) and stimulated gB-specific CD4  T cell
clones, even at relatively low input virus doses (Fig. 7 A).
The levels of IFN-  (500–1000 pg) that were produced by
CD4  T cells that were in contact with His16 cells that were
infected with only 0.5 PFU/cell of HCMV TR (Fig. 7 A)
were similar to those produced frequently with His16 cells
that were infected with AdtetgB or with DCs and exoge-
nous gB (Fig. 4). Moreover, there was substantial stimulation
of CD4  T cells when His16 cells were infected with ex-
tremely low doses (0.05 PFU/cell) of HCMV TR (Fig. 7 B).
Even at these low virus doses, it is likely that gB expression is
attained in a reasonable fraction of cells, because the HCMV
particle/PFU ratio is 150–1,000. It is possible that gB that
was part of the input virus was presented here, although this
might be unlikely given the very low input doses. In other
experiments, cells that were infected with UV-inactivated
HCMV TR were recognized poorly by T cells (unpublished
data). However, these UV-inactivated viruses were not
characterized in terms of gene expression and for the integ-
rity of virion proteins, and it is difficult to reach solid con-
clusions. More importantly, these results testify to the con-
clusion that these glial cells can present gB and stimulate
CD4  T cells when extremely low concentrations of gB are
present. Given previous observations that high protein con-
Figure 6. Endosomal targeting of endogenous gB is required for 
presentation. (A) WT gB contains a 135-residue cytosolic domain. gB CT 
is truncated three residues after the transmembrane (TM) domain. gB-KKSL 
contains the ER retention motif KKSL at the COOH terminus. gB-KKSLAL 
contains two additional residues that reverse the effects of KKSL. (B) His16 
cells were infected with Ad vectors expressing WT gB, gB-KKSL, gB-KKSLAL, 
or gB CT (50 PFUs/cell), and cell surface expression of gB was assessed by 
FACS. (C) His16 cells were infected with Ad viruses (50 PFUs/cell) for 24 h, 
fixed, permeabilized, and stained for gB (green) and HLA-DM (red) in the 
case of WT gB and gB CT, or protein disulfide isomerase (red) in the case of 
gB-KKSL. (D) His16 cells were infected with Ad viruses (1 PFU/cell) expressing 
WT gB, gB CT, gB-KKSL, gB-KKSLAL, or HSV gI for 24 h then incubated 
with anti-gB CD4  T cell clones. IFN-  was measured after 24 h.JEM VOL. 202, October 17, 2005 1115
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centrations were required for cytoplasmic antigens to be pre-
sented (51, 52), this supports efficient presentation.
HCMV TR was cloned recently by inserting a bacterial
artificial chromosome (BAC) into the HCMV US2-US6
genes to derive a virus denoted TR-BAC, which does not
express the unique short (US)2 and US3 proteins (50). We
showed previously, by using Ad vectors, that US2 and US3
can inhibit the class II pathway and block presentation of ex-
ogenous mtb39 to CD4  T cells (37, 45). However, effects
of US2 and US3 have been difficult to study in the context
of HCMV because of inefficient infection of any class II–
expressing cells. Here, we show that low doses of TR-BAC
(a US2 /US3  mutant) reproducibly stimulated two different
CD4  T cell clones 2.5-fold better than did WT TR that
expresses US2 and US3 (Fig. 7 B). This effect was not ob-
served at higher doses of virus (Fig. 7 A), probably because
higher levels of gB (perhaps in the input virus) overwhelmed
the effects of US2 and US3. This is the first demonstration of
the effects of US2 and US3 on class II presentation, in the
context of HCMV infection. Together, these data are con-
sistent with the notion that gB can be presented efficiently to
CD4  T cells when cells are infected with very low HCMV
doses, and that presentation in the context of HCMV in-
fected cells can be reduced by US2 and US3.
DISCUSSION
HCMV elicits a robust and long-lasting cellular immune re-
sponse that includes enormous numbers of CD4  and CD8 
T cells (23). These T cells are essential for the control of virus
in vivo. Clearly, anti-HCMV CD4  T cells play an impor-
tant role in expanding CD8  T cell populations, as evidenced
by the failure of anti-HCMV CD8  T cell therapy in immu-
nosuppressed patients who lack CD4  T cell “help” (53).
However, there also is evidence that HCMV-specific CD4 
T cells can play a key role as effectors to contain or eliminate
the virus. CD4  T cell clones that are specific for several
HCMV proteins were described to possess cytolytic activity
(17, 29–31), although it might be argued that this was ac-
quired in vitro. Observations that HCMV assembly and class
II antigen presentation pathways intersect in endosomal com-
partments predict that there is extensive presentation of en-
dogenous viral proteins by class II molecules. It is highly un-
likely that in important host cells—epithelial, endothelial, and
glial cells—this presentation is associated with priming of host
immunity. Instead, we hypothesized that class II presentation
in these cells relates to recognition of HCMV infection by
CD4  effector T cells, and provides a mechanism for control
of virus in addition to CD8  T cells.
Based on these considerations, we initially asked whether
HCMV-specific CD4  T cells were cytolytic in vivo. A
substantial fraction of freshly isolated CD4  T cells re-
sponded to glial cells presenting endogenous gB by express-
ing granzyme B. Although, it also is possible that gB-specific
CD4  T cells use the Fas-Fas ligand–mediated lytic mecha-
nism, the observation that the frequency of granzyme
B–secreting T cells was similar to those producing IFN- 
supported the notion that granule exocytosis is a major path-
way for cytotoxicity of anti-gB CD4  CTLs. Granzyme re-
lease is an event downstream of polyperforin pore formation
on target cell membranes, and these concerted events di-
rectly correlate with the lytic activity of CTLs (38, 54). The
observation that endogenous gB presented by glial cells is
recognized by circulating CD4  T cell effectors supports a
direct role for these immune cells in controlling the virus. In
addition, our study connects HCMV replication in these bi-
ologically relevant cells to potentially abundant and func-
tionally important CD4  CTLs. This is one of a very few
examples in which evidence supports the existence of anti-
viral CD4  CTLs in vivo, and suggests that these cells are
more widespread than believed previously.
Endogenous HCMV gB was presented efficiently by en-
dothelial, glial, and epithelial cells. Glial cells expressing ex-
tremely low levels of gB—delivered by using an Ad vector
or after HCMV infection—stimulated CD4  T cells as well
as, or better than, DCs that were incubated with exogenous
gB. This presentation required sorting to endosomes and en-
dosomal proteases. gB targeted to the plasma membrane or
retained in the ER was not presented well. Given that
HCMV assembles in endosomes, it is highly probable that
this pathway extends to most other HCMV structural pro-
teins. Consistent with this, a second HCMV glycoprotein,
gH, is an important target of anti-HCMV CD4  T cells
(31). Other herpesviruses (HSV, EBV, varicella-zoster virus,
and Kaposi’s sarcoma–associated herpesvirus) also infect en-
dothelial, glial, or epithelial cells and similarly assemble in
TGN/endosomes. Thus, we believe that class II presenta-
Figure 7. Presentation of gB in HCMV-infected cells. His16 cells were 
infected with WT HCMV strain TR or TR-BAC lacking the US2 and US3 genes 
using 0.5 PFU/cell (A) or 0.05 PFU/cell (B) for 72 h and incubated with anti-gB 
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tion of endosome-sorted herpesvirus proteins probably is a
prevalent process.
Endothelial, epithelial, and glial cells failed to present ex-
ogenous, soluble gB, yet His16 glial cells could present a sol-
uble TB protein. Uptake of gB was slow, and it is reasonable
that delivery to loading compartments also was slow or inef-
ficient. Alternatively, exogenous gB may be delivered into
endosomal subcompartments that contain a different set of
proteases compared with those that endogenous gB encoun-
ters. Endogenous, membrane-anchored gB traffics internally
in recycling loops between the TGN and endosomes (39).
Previous studies observed that different subcellular compart-
ments produce distinct epitopes from the same protein, or
may destroy other epitopes (7, 55, 56). Mapping of gB
epitopes, combined with cell fractionation studies, might
produce a better picture of why soluble gB is not presented.
However, this is beyond the scope of present studies and is
not directly relevant because endogenous gB, and not solu-
ble gB, is produced during HCMV infection.
Several studies have described class II presentation of en-
dogenous viral antigens by mechanisms that differ from that
described here. Measles virus proteins were presented by
TAP-dependent or -independent pathways, although the
cytoplasmic matrix protein required high and sustained levels
of expression compared with class I presentation (51, 52).
Certain epitopes derived from influenza virus membrane
proteins were presented in a proteasome- and TAP-depen-
dent class II pathway, whereas other epitopes were presented
only as exogenous antigens (7, 10). Unlike HCMV and
other herpesviruses, influenza and measles viruses assemble at
the plasma membrane without the requirement for sorting
to, or accumulation in, endosomes. EBV expresses a limited
set of viral proteins in latently infected B cells, and a nuclear
antigen, EBV nuclear antigen-1, is delivered to endosomes
by autophagy and then is presented by class II molecules (6).
These observations, together with our results, provide an ap-
preciation that CD4  T cells recognize endogenous viral an-
tigens by a variety of mechanisms, and that this recognition
has important implications for the control of viral infections.
Class II presentation of endogenous HCMV antigens pro-
vides an explanation for previous observations that this virus
also inhibits the MHC class II pathway (33, 37, 45). At the
outset, these findings might seem to be a contradiction.
However, it is well established that HCMV expresses inhibi-
tors of the class I pathway and NK cell recognition, and yet,
the virus is controlled amply by CD8  and NK cells (33, 57,
58). HCMV immune evasion proteins do not affect immune
priming as reflected by robust CD8  and CD4  T responses,
and inhibition of antigen presentation is inefficient in profes-
sional APCs (40, 59, 60). Instead, this avoidance reduces the
recognition of virus-infected cells, likely within a narrow
window of time (e.g., following reactivation) or involving
specific cell types (e.g., nonprofessional APCs, such as epithe-
lial, endothelial, or glial cells) (57). Thus, class II presentation
of endogenous viral proteins to CD4  T cells increases the
host’s capacity to recognize the virus in the face of inhibition
of CD8  T and NK cell recognition, and is, itself, the subject
of immune evasion. Here, by using a clinical strain of
HCMV, we showed that US2 and US3 reduced class II pre-
sentation of gB in HCMV-infected glial cells. The effects of
US2 and US3 were most prominent at low doses of HCMV,
conditions that may reflect infection in vivo where modest
differences may provide a substantial selective advantage, es-
pecially in cells that express lower levels of class II proteins.
The fact that HCMV can inhibit the class II pathway, under
certain circumstances, attests to the notion that presentation
of endogenous proteins in nonprofessional APCs is an impor-
tant mechanism by which HCMV is recognized by the im-
mune system, and is something that must be thwarted.
MATERIALS AND METHODS
Cells and media. His16 and 2E12 cells were derived by stable transfection
of U373-MG or AGS cells, respectively, with the human CIITA gene (37,
40, 41). BB19 (61), DMVEC (62), and HPV-AEC endothelial cell lines
were obtained from A. Moses (Oregon Health & Science University, Port-
land, Oregon), and were grown in endothelial cell basal medium-2 and sup-
plements. 293 cells used to propagate adenovirus (Ad) vectors were main-
tained in Eagle’s minimum essential medium plus 10% FBS, and fibroblasts
were grown in DMEM plus 10% FBS. DCs were prepared and maintained
as described (46). Tn5 insect cells were grown in Grace’s insect cell media.
Cloning and expansion of T cells. Human blood and sera were ob-
tained according to human subjects protocol approved by Institutional Re-
view Boards at Oregon Health & Science University and Portland Veterans
Administration Medical Center. CD4  T cells, from HLA-DRB17  indi-
viduals to match the DR type of His16 cells, were purified from PBMCs
using CD8 midi-MACS columns (Dynal). T cell frequencies were assessed
by ELISPOT, using PBMCs. T cells were expanded, using autologous DCs
and macrophage, cloned by limiting dilution using allo-PBMCs and allo-
lymphoblastoid cell lines (LCLs) (46, 63), and tested by ELISPOT for reac-
tivity with soluble gB using DCs. Clones were expanded using  -irradiated
allo-LCLs and allo-PBMCs, anti-CD3 mAb (Chiron), and IL-2 (46, 63).
Viruses. WT and mutant human CMV (HCMV) strain TR (50) were
propagated and titered on fibroblasts. The virus was purified using sorbitol
cushion and sucrose gradients. Ad vectors expressing mutant forms of
HCMV gB were constructed similar to those of HCMV US2 and US3 (37,
45), HSV gI (64), and WT gB (48). The promoter for all Ad vectors is in-
duced when cells are co-infected with a second vector, Adtet-trans. An Ad
vector expressing mtb39 fused to IL-1 signal sequence (AdTbH9) (46), as
well as a baculovirus encoding His-tagged HCMV gB extracellular domain
encompassing residues 1–692 (42), have been described.
Protein and peptide antigens. HCMV-infected cell extracts were pre-
pared by freeze-thawing infected fibroblasts. Soluble recombinant HCMV
gB and HSV gE/gI dimer were produced and purified as described (42, 65).
Soluble mtb39 was obtained from Corixa. HCMV gB and UL18 peptide
pools consisting of 15-mers overlapping by 10 residues, synthesized at Mim-
otopes Inc., were obtained from L. Picker (Oregon Health & Science Uni-
versity, Portland, Oregon).
Antibodies, confocal microscopy, and flow cytometry. mAb 27–78
(66) and rabbit antisera to gB were obtained from W. Britt (University of
Alabama, Birmingham, AL). Antibodies to protein disulfide isomerase
(StressGen Biotechnologies), TGN46 (Serotec), and HLA-DM  (BD Bio-
sciences), as well as Alexa 488-conjugated donkey anti–sheep and goat anti–
mouse IgG and Alexa 594-conjugated goat anti–rabbit IgG (Invitrogen)JEM VOL. 202, October 17, 2005 1117
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were purchased commercially. Immunofluorescence and flow cytometry
were performed as described (45).
Endocytosis assay. Soluble gB was labeled with Na125I using Iodobeads
(Pierce Chemical Co.). Cells were incubated with 125I-gB at 4 C for 15
min, warmed to 37 C to allow internalization and, at various times, cell sur-
face gB was stripped from cells by a 10-min incubation with citrate buffer
(40 mM citric acid, 10 mM KCl, 135 mM NaCl, pH 3.0) at 4 C. Internal-
ized gB was determined by counting cell-associated radioactivity.
CD4  T cell assays. Antigen presentation assays were performed in 96-
well plates (37, 45). In brief, 104 APCs were infected with Ad vectors for 18 h
or were left uninfected, and then were incubated for 18–24 h with 4  
104 CD4  T cells. Endothelial cells were treated with IFN-  (50 U/ml,
Immunex) for 24 h before infection. Soluble antigens were added 0–4 h be-
fore addition of T cells. For drug inhibition studies, cells were incubated
with the compounds for 30 min before and during Ad infection or soluble
protein addition, fixed with 0.1% p-formaldehyde for 5 min, and washed
and incubated with T cells for 18–24 h. For studies with HCMV, cells were
infected for 72 h before T cells were added. Secretion of IFN-  by the T
cells was detected by a sandwich ELISA (45). For granzyme B ELISPOT as-
says (67), MACS-purified CD4  T cells were incubated with His16 cells
that were infected with AdtetgB or AdtetgI.
CTL assays. 51Cr release assays were used to measure cytotoxicity (68). In
brief, His16 cells were infected with Ad vectors for 18 h, labeled with
Na2
51CrO4 (100  Ci/106 cells) for 1–2 h, and plated at 104/well in tripli-
cate with various numbers of CD4  T cells for 24 h. Percentage specific ly-
sis was calculated based on maximal release measured by using 2% Nonidet
P-40. Spontaneous release was never  30%.
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